The evolution of coronary stents

References

• Roger V, Go A, Lloyd-Jones D, et al. For the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.
   PubMed Web of Science ®Google Scholar
• Forssmann W. Die Sondierung des rechten herzens. Klin Wochenschr. 1929;2085–2087.
   Google Scholar
• Cournand A, Ranges H. Catheterization of the right auricle in man. Proc Soc Exp Biol Med. 1941;46:62.
   Google Scholar
• Seldinger S. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol. 1953;39:368–376.
   PubMed Web of Science ®Google Scholar
• Sones F. Cine-cardio-angiography. Pediatr Clin North Am. 1958;5:945–979.
   PubMedGoogle Scholar
• Dotter C, Judkins M. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. Circulation. 1964;30:654–670.
   PubMed Web of Science ®Google Scholar
• Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1:263.
   PubMed Web of Science ®Google Scholar
• Simpson J, Baim D, Robert E, et al. A new catheter system for coronary angioplasty. Am J Cardiol. 1982;49:1216–1222.
   PubMed Web of Science ®Google Scholar
• Bonzel T, Wollschlager H, Just H. A new catheter system for the mechanical dilatation of coronary stenoses with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. Biomed Tech. 1986;31:195–200.
   PubMedGoogle Scholar
• Venkitachalam L, Kip K, Selzer F, et al. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv. 2009;2:6–13.
   PubMed Web of Science ®Google Scholar
• Huber M, Mooney J, Madison J, et al. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol. 1991;68:467–471.
   PubMed Web of Science ®Google Scholar
• Lincoff A, Popma J, Ellis S, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926–935.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Gunn J, Serruys P. Coronary stents: historical development, current status and future directions. Br Med Bull. 2013;106:193–211.
   PubMed Web of Science ®Google Scholar
• Pendyala L, Jabara R, Robinson K, et al. Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. J Interv Cardiol. 2009;22:37–48.
   PubMed Web of Science ®Google Scholar
• Serruys P, Rutherford J. The birth, and evolution, of percutaneous coronary interventions: a conversation with Patrick Serruys. Circulation. 2016;134(2):97–100.
   PubMed Web of Science ®Google Scholar
• Palmaz J, Sibbitt R, Reuter SR, et al. Expandable intraluminal graft: a preliminary study: work in progress. Radiology. 1985;156:73–77.
   PubMed Web of Science ®Google Scholar
• Schatz R, Palmaz J, Tio F, et al. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76:450–457.
   PubMed Web of Science ®Google Scholar
• Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701–706.
   PubMed Web of Science ®Google Scholar
• Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85:916–927.
   PubMed Web of Science ®Google Scholar
• Schatz R. A view of vascular stents. Circulation. 1989;79:445–457.
   PubMed Web of Science ®Google Scholar
• Serruys P, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489–495.
   PubMed Web of Science ®Google Scholar
• Savage M, Fischman D, Rake R, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol. 1998;31:307–311.
   PubMed Web of Science ®Google Scholar
• Holmes D, Savage M, LaBlanche J, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106:1243–1250.
   PubMed Web of Science ®Google Scholar
• Serruys P, Strauss B, Beatt K, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–17.
   PubMed Web of Science ®Google Scholar
• Morice M, Serruys P, Sousa J, et al. RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.
   PubMed Web of Science ®Google Scholar
• Yokol H, Kimura T, Nakagawa Y, et al. Long-term clinical and quantitative angiographic follow-up after the Palmaz–Schatz stent restenosis. J Am Coll Cardiol. 1996;27:224.
   Google Scholar
• Moliterno D. Healing Achilles–sirolimus versus paclitaxel. N Engl J Med. 2005;353:724–727.
   PubMed Web of Science ®Google Scholar
• Hoffmann R, Jansen C, Konig A, et al. Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur Heart J. 2001;22:2007–2014.
   PubMed Web of Science ®Google Scholar
• Ormiston J, Dixon S, Webster M, et al. Stent longitudinal flexibility: a comparison of 13 stent designs before and after balloon expansion. Catheter Cardiovasc Interv. 2000;50:120–124.
   PubMed Web of Science ®Google Scholar
• Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533.
   PubMed Web of Science ®Google Scholar
• Rossini R, Musumeci G, Alessandro, et al. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10:49–61.
   PubMed Web of Science ®Google Scholar
• Bertrand O, Sipehia R, Mongrain R, et al. Biocompatibility aspects of new stent technology. J Am Coll Cardiol. 1998;32:562–571.
   PubMed Web of Science ®Google Scholar
• Heldman A, Cheng L, Jenkins G, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289–2295.
   PubMed Web of Science ®Google Scholar
• Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 2003;107(17):21–80.
   PubMed Web of Science ®Google Scholar
• Abal M, Andreu J, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193–203.
   PubMed Web of Science ®Google Scholar
• Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–2170.
   PubMed Web of Science ®Google Scholar
• Marx S, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–855.
   PubMed Web of Science ®Google Scholar
• Moses J, Leon M, Popma J, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323.
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick A, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099.
   PubMed Web of Science ®Google Scholar
• Schampaert E, Cohen M, Schluter F, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115.
   PubMed Web of Science ®Google Scholar
• Grube E, Silber S, Hauptmann K, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42.
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. Circulation. 2003;108:788–794.
   PubMed Web of Science ®Google Scholar
• Stone G, Ellis S, Cox D, et al. TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942–1947.
   PubMed Web of Science ®Google Scholar
• Laarman G, Suttorp M, Dirksen M, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105–1113.
   PubMed Web of Science ®Google Scholar
• Stone G, Moses J, Ellis S, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, von Beckerath N, et al. ISAR-DESIRE study investigators: sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. Jama. 2005;293:165–171.
   PubMed Web of Science ®Google Scholar
• Goy J, Stauffer J, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. The TAXi trial. J Am Coll Cardiol. 2005;45:308–311.
   PubMed Web of Science ®Google Scholar
• Mani G, Feldman M, Patel D, et al. Coronary stents: a materials perspective. Biomaterials. 2007;28:1689–1710.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama. 2005;293:2126–2130.
   PubMed Web of Science ®Google Scholar
• McFadden E, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521.
   PubMed Web of Science ®Google Scholar
• Stone G, Ellis S, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4:530–542.
   PubMed Web of Science ®Google Scholar
• Holmvang L, Kelbæk H, Kaltoft A, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6(6):548–553.
   PubMed Web of Science ®Google Scholar
• De Luca G, Dirksen MT, Spaulding C, et al. Drug-Eluting Stent in Primary Angioplasty (DESERT) cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172:611–621.
   PubMedGoogle Scholar
• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–1145.
   PubMed Web of Science ®Google Scholar
• Carter A, Aggarwal M, Kopia G, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617–624.
   PubMed Web of Science ®Google Scholar
• Menown I, Noad R, Garcia EJ, et al. The platinum chromium element stent platform: from alloy, to design, to clinical practice. Adv Ther. 2010;27:129–141.
   PubMed Web of Science ®Google Scholar
• O’Brien B, Stinson J, Larsen S, et al. A platinum-chromium steel for cardiovascular stents. Biomaterials. 2010;31:3755–3761.
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn A, et al. Endothelial cell recovery between comparator polymer-based drug eluting stents. J Am Coll Cardiol. 2008;52:333–342.
   PubMed Web of Science ®Google Scholar
• Nebeker J, Virmani R, Bennett C, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175–181.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Serruys PW, Kereiakes, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (clinical evaluation of the xience v everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv. 2013;6:914–922.
   PubMed Web of Science ®Google Scholar
• Camenzind E, Wijns W, Mauri L, et al. Committee PS, Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380:1396–1405.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Serruys P, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6):e002230.
   PubMed Web of Science ®Google Scholar
• Wijns W, Steg P, Mauri L, et al. PROTECT steering committee and investigators. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. Eur Heart J. 2014;35:2812–2820.
   PubMed Web of Science ®Google Scholar
• Serruys P, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–146.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Stefanini GG, Franzone A, et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv. 2015;8:e002223.
   PubMed Web of Science ®Google Scholar
• Stone G, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–1674.
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef K, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201–209.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873–2891.
   PubMed Web of Science ®Google Scholar
• Collet J, Silvain J, Kerneis M, et al. ARCTIC investigators. clinical outcome of first- vs second-generation DES according to DAPT duration: results of ARCTIC-generation. Clin Cardiol. 2016;39:192–200.
   PubMed Web of Science ®Google Scholar
• Stefanini G, Siontis G, Cao D, et al. Short versus long duration of DAPT after DES implantation: a meta-analysis. J Am Coll Cardiol. 2014;64:953–954.
   PubMed Web of Science ®Google Scholar
• Pandit A, Giri S, Hakim F. Shorter (<6 months) versus longer (12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2015;85:34–40.
   PubMed Web of Science ®Google Scholar
• El-Hayek G, Messerli F, Bangalore S, et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol. 2014;114:236–242.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network metaanalysis. J Am Coll Cardiol. 2015;65:1092–1102.
   PubMed Web of Science ®Google Scholar
• Windecker S, Alfonso F, Collet P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS), developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
   PubMed Web of Science ®Google Scholar
• Obata JE, Kitta Y, Takano H, et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol. 2007;50:1305–1309.
   PubMed Web of Science ®Google Scholar
• Park S, Kang S, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051–2057.
   PubMed Web of Science ®Google Scholar
• Byrne R, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57:567–584.
   PubMedGoogle Scholar
• Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701–705.
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys P. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56:S43–78.
   PubMed Web of Science ®Google Scholar
• Byrne R, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial versus polymer-based drug-eluting stents. Eur Heart J. 2009;30:923–931.
   PubMed Web of Science ®Google Scholar
• Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3:174–183.
   PubMed Web of Science ®Google Scholar
• Urban P, Abizaid A, Chevalier B, et al. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J. 2013;165:704–709.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith I, Abizaid A, et al. LEADERS FREE Investigators.Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–2047.
   PubMed Web of Science ®Google Scholar
• Mehilli J, Byrne R, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J. 2008;29:1975–1982.
   PubMed Web of Science ®Google Scholar
• Byrne R, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441–2449.
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys P, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163–1173.
   PubMed Web of Science ®Google Scholar
• Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention. 2008;4:59–63.
   PubMedGoogle Scholar
• Stefanini G, Byrne R, Serruys P, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214–1222.
   PubMed Web of Science ®Google Scholar
• Kereiakes D, Meredith I, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circ Cardiovasc Interv. 2015;8(4):e002372. Available from: http://circinterventions.ahajournals.org/content/8/4/e002372.long
   Web of Science ®Google Scholar
• Mennuni MG, Stefanini GG, Pagnotta PA, et al. Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients. EuroIntervention. 2017;12:1978–1986.
   PubMedGoogle Scholar
• Sarno G, Lagerqvist B, Olivecrona G, et al. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheter Cardiovasc Interv. 2017;90:881–887.
   PubMed Web of Science ®Google Scholar
• Ormiston J, Serruys P. Bioabsorbable coronary stents. Circ Cardiovasc Interventions. 2009;2:255–260.
   PubMed Web of Science ®Google Scholar
• Oberhauser J, Hossainy S, Rapoza R. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009;5:F15–22.
   PubMedGoogle Scholar
• Serruys P, Luijten H, Beatt K, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361–371.
   PubMed Web of Science ®Google Scholar
• Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol. 2006;18:70–74.
   PubMedGoogle Scholar
• Tanimoto S, Serruys P, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70:515–523.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Serruys P, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv. 2011;78:3–12.
   PubMed Web of Science ®Google Scholar
• Serruys P, Onuma Y, Ormiston J, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122:2301–2312.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Serruys P, Perkins L, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122:2288–2300.
   PubMed Web of Science ®Google Scholar
• Gogas B, Radu M, Onuma Y, et al. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging. 2012;28:499–511.
   PubMed Web of Science ®Google Scholar
• Gogas B. Bioresorbable scaffolds for percutaneous coronary interventions. Glob Cardiol Sci Pract. 2014;4:409–427.
   Google Scholar
• Caiazzo G, Kilic I, Fabris E, et al. Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience? Int J Cardiol. 2015;201:129–136.
   PubMed Web of Science ®Google Scholar
• Ormiston J, Serruys P, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2015;371:899–907.
   Google Scholar
• Serruys P, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.
   PubMed Web of Science ®Google Scholar
• Ellis S, Kereiakes D, Metzger D, et al. ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–1915.
   PubMed Web of Science ®Google Scholar
• Cassese S, Byrne R, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomized controlled trials. Lancet. 2016;387:537–544.
   PubMed Web of Science ®Google Scholar
• Lipinski M, Escarcega R, Baker N, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold. J Am Coll Cardiol Intv. 2016;9:12–24.
   Google Scholar
• Puricel S, Cuculi F, Weissner M, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921–931.
   PubMed Web of Science ®Google Scholar
• Serruys P, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–2491.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. U.S. Department of Health and Human Services. [cited 2017 Sep 22nd]. Available from: https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm546808.htm
   Google Scholar
• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967.
   PubMed Web of Science ®Google Scholar
• Walter DH, Rittig K, Bahlmann F, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017–3024.
   PubMed Web of Science ®Google Scholar
• Aoki J, Serruys P, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol. 2005;45:1574–1579.
   PubMed Web of Science ®Google Scholar
• Duckers H, Silber S, de Winter R, et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention. 2007;3:67–75.
   PubMedGoogle Scholar
• Duckers H, Soullie T, den Heijer P, et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention. 2007;3:350–358.
   PubMedGoogle Scholar
• Beijk M, Klomp M, Van Geloven N, et al. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study. Catheter Cardiovasc Interv. 2011;78:189–195.
   PubMed Web of Science ®Google Scholar
• Klomp M, Beijk M, Varma C, et al. 1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc Interv. 2011;4:896–904.
   PubMed Web of Science ®Google Scholar
• Haude M, Lee S, Worthley S, et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6:334–343.
   PubMed Web of Science ®Google Scholar
• Moreno R, Fernández C, Hernández R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–959.
   PubMed Web of Science ®Google Scholar
• Machecourt J, Danchin N, Lablanche J, et al. EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50:501–508.
   PubMed Web of Science ®Google Scholar
• Kang S, Cho Y, Park G, et al. Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation. Am J Cardiol. 2013;111:1408–1414.
   PubMed Web of Science ®Google Scholar
• Honda Y, Muramatsu T, Ito Y, et al. Impact of ultra-long second-generation drug-eluting stent implantation. Catheter Cardiovasc Interv. 2015;87:E44–53.
   PubMed Web of Science ®Google Scholar
• Choi I, Koh Y, Lim S, et al. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. Am J Cardiol. 2014;113:457–464.
   PubMed Web of Science ®Google Scholar
• Ormiston J, Mahmud E, Turco M, et al. Direct stenting with the TAXUS Liberté drug-eluting stent: results from the Taxus Atlas Direct Stent Study. JACC Cardiovasc Interv. 2008;1:150–160.
   PubMed Web of Science ®Google Scholar
• Azzalini L, Millán X, Ly H, et al. Direct stenting versus pre-dilation in ST-elevation myocardial infarction: a systematic review and meta-analysis. J Interv Cardiol. 2015;28:119–131.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Koga H, Serikawa T, et al. Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion. Catheter Cardiovasc Interv. 2009;73:205–211.
   PubMed Web of Science ®Google Scholar
• Saha M, Poliacikova P, de Belder A, et al. Coronary stent implantation technique: prolonged inflation time maximizes stent expansion. J Invasive Cardiol. 2013;25:28–31.
   PubMed Web of Science ®Google Scholar
• Shand JA, Sharma D, Hanratty C, et al. A prospective intravascular ultrasound investigation of the necessity for and efficacy of postdilation beyond nominal diameter of 3 current generation DES platforms for the percutaneous treatment of the left main coronary artery. Catheter Cardiovasc Interv. 2014;84:351–358.
   PubMed Web of Science ®Google Scholar